verapamil has been researched along with Dementia Praecox in 19 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The antipsychotic effects of verapamil were tested in a double-blind, placebo-controlled, randomized study in 18 patients who met Research Diagnostic Criteria for acute schizophrenia." | 9.06 | Antipsychotic effects of verapamil in schizophrenia. ( Price, WA, 1987) |
| "Cerebrospinal fluid (CSF) and plasma levels of verapamil and its two metabolites, norverapamil and D-620, were measured in seven patients with schizophrenia under steady-state conditions." | 7.67 | Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia. ( Blumhardt, CL; Doran, AR; Narang, PK; Pickar, D, 1988) |
| "The antipsychotic effects of verapamil were tested in a double-blind, placebo-controlled, randomized study in 18 patients who met Research Diagnostic Criteria for acute schizophrenia." | 5.06 | Antipsychotic effects of verapamil in schizophrenia. ( Price, WA, 1987) |
| " We detected potential therapeutic compounds as well as anisomycin in schizophrenia (false discovery rate (FDR)-q = 0." | 4.02 | Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates. ( Konuma, T; Ogawa, K; Okada, Y, 2021) |
| "Cerebrospinal fluid (CSF) and plasma levels of verapamil and its two metabolites, norverapamil and D-620, were measured in seven patients with schizophrenia under steady-state conditions." | 3.67 | Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia. ( Blumhardt, CL; Doran, AR; Narang, PK; Pickar, D, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (73.68) | 18.7374 |
| 1990's | 3 (15.79) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (5.26) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Konuma, T | 1 |
| Ogawa, K | 1 |
| Okada, Y | 1 |
| de Klerk, OL | 1 |
| Willemsen, AT | 1 |
| Bosker, FJ | 1 |
| Bartels, AL | 1 |
| Hendrikse, NH | 1 |
| den Boer, JA | 1 |
| Dierckx, RA | 1 |
| Liao, WB | 1 |
| Bullard, MJ | 1 |
| Kuo, CT | 1 |
| Hsiao, CT | 1 |
| Chu, PH | 1 |
| Chiang, CW | 1 |
| Bartko, G | 1 |
| Horvath, S | 1 |
| Zador, G | 1 |
| Frecska, E | 1 |
| Wells, BG | 1 |
| Reiter, S | 1 |
| Adler, L | 1 |
| Angrist, B | 1 |
| Peselow, E | 1 |
| Rotrosen, J | 1 |
| Schepelern, S | 1 |
| Køster, A | 1 |
| Narang, PK | 3 |
| Blumhardt, CL | 1 |
| Doran, AR | 3 |
| Pickar, D | 3 |
| Price, WA | 4 |
| Uhr, SB | 2 |
| Jackson, K | 1 |
| Berger, PA | 2 |
| Csernansky, JG | 1 |
| Grebb, JA | 1 |
| Shelton, RC | 1 |
| Taylor, EH | 1 |
| Bigelow, LB | 1 |
| Wolkowitz, OM | 2 |
| Labarca, R | 1 |
| Roy, A | 2 |
| Breier, A | 2 |
| Tourjman, SV | 2 |
| Bloom, DM | 2 |
| Nair, NP | 2 |
| Pascarzi, GA | 1 |
| Pascarzi, G | 1 |
| Giannini, AJ | 2 |
| Adriaenssens, PI | 1 |
| Ciaranello, RD | 1 |
| Meigs, CY | 1 |
1 review available for verapamil and Dementia Praecox
| Article | Year |
|---|---|
Verapamil in the treatment of schizophrenia.
Topics: Humans; Schizophrenia; Verapamil | 1990 |
4 trials available for verapamil and Dementia Praecox
| Article | Year |
|---|---|
Antipsychotic effects of verapamil in schizophrenia.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged | 1987 |
A negative, double-blind, placebo-controlled, clinical trial of verapamil in chronic schizophrenia.
Topics: Adolescent; Adult; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Humans; M | 1986 |
Clinical and biochemical effects of verapamil administration to schizophrenic patients.
Topics: Adult; Clinical Trials as Topic; Double-Blind Method; Emotions; Female; Homovanillic Acid; Hostility | 1987 |
Use of verapamil to treat negative symptoms in schizophrenia.
Topics: Adult; Double-Blind Method; Haloperidol; Humans; Male; Middle Aged; Schizophrenia; Verapamil | 1987 |
14 other studies available for verapamil and Dementia Praecox
| Article | Year |
|---|---|
Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates.
Topics: Anisomycin; COVID-19 Drug Treatment; Databases, Genetic; Databases, Pharmaceutical; Drug Development | 2021 |
Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
Topics: Adult; Analysis of Variance; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tra | 2010 |
Anticholinergic overdose induced torsade de pointes successfully treated with verapamil.
Topics: Adolescent; Antidepressive Agents; Antipsychotic Agents; Cholinergic Antagonists; Drug Overdose; Fem | 1996 |
Effects of adjunctive verapamil administration in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Humans; Male; Psychiatric Status Rati | 1991 |
Effects of verapamil on tardive dyskinesia and psychosis in schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Anxiety Disorders; Depressive Disorder; Dyskinesia, Drug-Induced; Hospi | 1989 |
Verapamil in treatment of severe schizophrenia.
Topics: Antipsychotic Agents; Drug Therapy, Combination; Humans; Schizophrenia; Verapamil | 1987 |
Steady-state cerebrospinal fluid transfer of verapamil and metabolites in patients with schizophrenia.
Topics: Administration, Oral; Adult; Blood Proteins; Blood-Brain Barrier; Chromatography, High Pressure Liqu | 1988 |
Effects of verapamil administration on negative symptoms of chronic schizophrenia.
Topics: Adult; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Schizophrenia; Schizophrenic Psy | 1988 |
Verapamil in the treatment of chronic schizophrenia.
Topics: Adult; Chronic Disease; Female; Humans; Male; Middle Aged; Schizophrenia; Verapamil | 1987 |
Verapamil in refractory schizophrenia: a case report.
Topics: Adult; Chronic Disease; Drug Resistance; Drug Therapy, Combination; Haloperidol; Humans; Male; Schiz | 1987 |
Treatment of schizophrenia with verapamil.
Topics: Adult; Humans; Male; Schizophrenia; Verapamil | 1986 |
Effect of verapamil on platelet serotonin concentration in normal and schizophrenic subjects.
Topics: Adult; Blood Platelets; Humans; Male; Middle Aged; Schizophrenia; Serotonin; Verapamil | 1986 |
Verapamil in acute psychosis.
Topics: Acute Disease; Humans; Psychotic Disorders; Schizophrenia; Verapamil | 1986 |
Verapamil concentrations in cerebrospinal fluid after oral administration.
Topics: Administration, Oral; Humans; Schizophrenia; Verapamil | 1985 |